

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-10. (Cancelled)

11. (Currently Amended) A method for stimulating an immune response in a patient, comprising administering to the patient a composition comprising a first component selected from the group consisting of physiologically acceptable carriers and immunostimulants, and a second component selected from the group consisting of:

- a) a polypeptide sequence comprising SEQ ID NO:475; and
- b) sequencees—polypeptides having at least 90% identity to the sequence polypeptide set forth in SEQ ID NO:475, wherein said polypeptides having at least 90% identity are immunologically reactive with an antibody and/or T cell that reacts with the polypeptide set forth in SEQ ID NO:475.

12. (New) A method for stimulating an immune response in a patient, comprising administering to the patient a composition comprising a first component selected from the group consisting of physiologically acceptable carriers and immunostimulants, and a second component comprising a polypeptide comprising at least 20 contiguous amino acids of the polypeptide set forth in SEQ ID NO:475, wherein said polypeptide comprising at least 20 contiguous amino acids is immunologically reactive with an antibody and/or T cell that reacts with the polypeptide set forth in SEQ ID NO:475.

13. (New) The method of claim 11 or 12 wherein said immunostimulant is selected from the group consisting of MPL®, QS21, QS7, Escin, Digitonin, Quil A, and a combination of monophosphoryl lipid A together with an aluminum salt.